{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T06:44:28Z","timestamp":1760251468938,"version":"build-2065373602"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,11]]},"DOI":"10.7759\/cureus.94371","type":"journal-article","created":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T06:26:37Z","timestamp":1760250397000},"source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Hyperuricemia on the Progression of Atherosclerotic Cardiovascular Disease"],"prefix":"10.7759","author":[{"given":"Marika","family":"Mdivnishvili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maia","family":"Kharebashvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vakhtang","family":"Chumburidze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kakha","family":"Nadaraia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lali","family":"Gujejiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketino","family":"Virkovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01916-y","article-title":"Hyperuricemia and its related diseases: mechanisms and advances in therapy","volume":"9","author":"Du L","year":"2024","unstructured":"Du L, Zong Y, Li H, et al.. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024, 9:212. 10.1038\/s41392-024-01916-y","journal-title":"Signal Transduct Target Ther"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-016-0379-z","article-title":"Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies","volume":"16","author":"Zuo T","year":"2016","unstructured":"Zuo T, Liu X, Jiang L, Mao S, Yin X, Guo L. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016, 16:207. 10.1186\/s12872-016-0379-z","journal-title":"BMC Cardiovasc Disord"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56100501","article-title":"Increased overall heart rate irregularity risk by hyperuricemia in the general population: results from the Korean national health and nutrition examination survey","volume":"56","author":"Eun Y","year":"2020","unstructured":"Eun Y, Han KD, Kim DH, et al.. Increased overall heart rate irregularity risk by hyperuricemia in the general population: results from the Korean national health and nutrition examination survey. Medicina (Kaunas). 2020, 56:10.3390\/medicina56100501","journal-title":"Medicina (Kaunas)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20065","article-title":"Hyperuricemia and coronary heart disease: a systematic review and meta-analysis","volume":"62","author":"Kim SY","year":"2010","unstructured":"Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010, 62:170-80. 10.1002\/acr.20065","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000443769","article-title":"Hyperuricemia, cardiovascular disease, and hypertension","volume":"3","author":"Kuwabara M","year":"2016","unstructured":"Kuwabara M. Hyperuricemia, cardiovascular disease, and hypertension. Pulse (Basel). 2016, 3:242-52. 10.1159\/000443769","journal-title":"Pulse (Basel)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s40885-020-00146-y","article-title":"Uric acid and cardiometabolic diseases","volume":"26","author":"Lee SJ","year":"2020","unstructured":"Lee SJ, Oh BK, Sung KC. Uric acid and cardiometabolic diseases. Clin Hypertens. 2020, 26:13. 10.1186\/s40885-020-00146-y","journal-title":"Clin Hypertens"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig DI","year":"2008","unstructured":"Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008, 359:1811-21. 10.1056\/NEJMra0800885","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2741\/3950","article-title":"Uric acid, hyperuricemia and vascular diseases","volume":"17","author":"Jin M","year":"2012","unstructured":"Jin M, Yang F, Yang I, Yin Y, Luo JJ, Wang H, Yang XF. Uric acid, hyperuricemia and vascular diseases. Front Biosci (Landmark Ed). 2012, 17:656-69. 10.2741\/3950","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.12612","article-title":"Uric acid and incident atrial fibrillation of 14 years population-based cohort study: the Suita Study","volume":"37","author":"Kobayashi T","year":"2021","unstructured":"Kobayashi T, Kokubo Y, Higashiyama A, et al.. Uric acid and incident atrial fibrillation of 14 years population-based cohort study: the Suita Study. J Arrhythm. 2021, 37:1215-9. 10.1002\/joa3.12612","journal-title":"J Arrhythm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012020","article-title":"Cohort Study of Repeated Measurements of Serum Urate and Risk of Incident Atrial Fibrillation","volume":"8","author":"Li S","year":"2019","unstructured":"Li S, Cheng J, Cui L, et al.. Cohort Study of Repeated Measurements of Serum Urate and Risk of Incident Atrial Fibrillation. J Am Heart Assoc. 2019, 8:e012020. 10.1161\/JAHA.119.012020","journal-title":"J Am Heart Assoc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106130","article-title":"Association of serum uric acid and coronary artery disease in premenopausal women","volume":"9","author":"Zhang JW","year":"2014","unstructured":"Zhang JW, He LJ, Cao SJ, Yang Q, Yang SW, Zhou YJ. Association of serum uric acid and coronary artery disease in premenopausal women. PLoS One. 2014, 9:e106130. 10.1371\/journal.pone.0106130","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-015-2878-1","article-title":"Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease","volume":"34","author":"Dai XM","year":"2015","unstructured":"Dai XM, Wei L, Ma LL, et al.. Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease. Clin Rheumatol. 2015, 34:1605-11. 10.1007\/s10067-015-2878-1","journal-title":"Clin Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2018.1467035","article-title":"Significance of asymptomatic hyperuricemia in patients after coronary events","volume":"78","author":"Tasi\u0107 I","year":"2018","unstructured":"Tasi\u0107 I, Kosti\u0107 S, Stojanovi\u0107 NM, et al.. Significance of asymptomatic hyperuricemia in patients after coronary events. Scand J Clin Lab Invest. 2018, 78:312-7. 10.1080\/00365513.2018.1467035","journal-title":"Scand J Clin Lab Invest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X16646703","article-title":"Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications","volume":"8","author":"Sattui SE","year":"2016","unstructured":"Sattui SE, Gaffo AL. Treatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implications. Ther Adv Musculoskelet Dis. 2016, 8:145-59. 10.1177\/1759720X16646703","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2016:4:2","article-title":"Uric acid and cardiovascular disease: an update","volume":"11","author":"Muiesan ML","year":"2016","unstructured":"Muiesan ML, Agabiti-Rosei C, Paini A, Salvetti M. Uric acid and cardiovascular disease: an update. Eur Cardiol. 2016, 11:54-9. 10.15420\/ecr.2016:4:2","journal-title":"Eur Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-1-10","article-title":"Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle","volume":"1","author":"Hayden MR","year":"2004","unstructured":"Hayden MR, Tyagi SC. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond). 2004, 1:10. 10.1186\/1743-7075-1-10","journal-title":"Nutr Metab (Lond)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206432","article-title":"When gout goes to the heart: does gout equal a cardiovascular disease risk factor?","volume":"74","author":"Singh JA","year":"2015","unstructured":"Singh JA. When gout goes to the heart: does gout equal a cardiovascular disease risk factor?. Ann Rheum Dis. 2015, 74:631-4. 10.1136\/annrheumdis-2014-206432","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/852954","article-title":"Review of hyperuricemia as new marker for metabolic syndrome","volume":"2014","author":"Billiet L","year":"2014","unstructured":"Billiet L, Doaty S, Katz JD, Velasquez MT. Review of hyperuricemia as new marker for metabolic syndrome. ISRN Rheumatol. 2014, 2014:852954. 10.1155\/2014\/852954","journal-title":"ISRN Rheumatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2014070660","article-title":"Uric acid and cardiovascular events: a Mendelian randomization study","volume":"26","author":"Kleber ME","year":"2015","unstructured":"Kleber ME, Delgado G, Grammer TB, et al.. Uric acid and cardiovascular events: a Mendelian randomization study. J Am Soc Nephrol. 2015, 26:2831-8. 10.1681\/ASN.2014070660","journal-title":"J Am Soc Nephrol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027089","article-title":"Elevated uric acid is associated with new-onset atrial fibrillation: results from the Swedish AMORIS cohort","volume":"12","author":"Ding M","year":"2023","unstructured":"Ding M, Viet NN, Gigante B, Lind V, Hammar N, Modig K. Elevated uric acid is associated with new-onset atrial fibrillation: results from the Swedish AMORIS cohort. J Am Heart Assoc. 2023, 12:e027089. 10.1161\/JAHA.122.027089","journal-title":"J Am Heart Assoc"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq146","article-title":"A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women","volume":"31","author":"Conen D","year":"2010","unstructured":"Conen D, Ridker PM, Everett BM, et al.. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J. 2010, 31:1730-6. 10.1093\/eurheartj\/ehq146","journal-title":"Eur Heart J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3282f240bf","article-title":"Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system","volume":"26","author":"Corry DB","year":"2008","unstructured":"Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008, 26:269-75. 10.1097\/HJH.0b013e3282f240bf","journal-title":"J Hypertens"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000087713","article-title":"Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter","volume":"25","author":"Kang DH","year":"2005","unstructured":"Kang DH, Han L, Ouyang X, et al.. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. Am J Nephrol. 2005, 25:425-33. 10.1159\/000087713","journal-title":"Am J Nephrol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.116.07650","article-title":"Relations of arterial stiffness and brachial flow-mediated dilation with new-onset atrial fibrillation: the Framingham heart study","volume":"68","author":"Shaikh AY","year":"2016","unstructured":"Shaikh AY, Wang N, Yin X, et al.. Relations of arterial stiffness and brachial flow-mediated dilation with new-onset atrial fibrillation: the Framingham heart study. Hypertension. 2016, 68:590-6. 10.1161\/HYPERTENSIONAHA.116.07650","journal-title":"Hypertension"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404161-the-impact-of-hyperuricemia-on-the-progression-of-atherosclerotic-cardiovascular-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T06:26:38Z","timestamp":1760250398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404161-the-impact-of-hyperuricemia-on-the-progression-of-atherosclerotic-cardiovascular-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.94371","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,11]]}}}